ASND 241220 145.00C (ASND241220C145000) Stock Options, News & Quotes - Moomoo

US OptionsDetailed Quotes

ASND241220C145000

Watchlist

1.80
-0.95-34.55%

15min DelayClose Nov 29 13:00 ET

1.80High1.80Low

Intraday

5D
Daily

News

JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Seeking AlphaNov 25 13:58 ET
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Seeking AlphaNov 19 11:06 ET
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Moomoo NewsNov 19 03:36 ET · Ratings
Express News | Ascendis Pharma A/S : Citigroup Cuts Target Price to $200 From $207
ReutersNov 18 06:25 ET
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $207
Moomoo NewsNov 16 08:00 ET · Ratings
Express News | Acendis Pharma Shares Are Trading Higher After Stifel Maintained a Buy Rating on the Stock and Raised Its Price Target From $200 to $207
BenzingaNov 15 12:08 ET

Comments

$Pfizer (PFE.US)$ could see 32$ before the end of tomorrow , keep an eye $GlaxoSmithKline (GSK.US)$ $Summit Therapeutics (SMMT.US)$ $Ascendis Pharma A/S (ASND.US)$

1

$Ascendis Pharma A/S (ASND.US)$ big rebound from drop after financials , from 111 to 150. that's a good profit for those who payed attention. $NVIDIA (NVDA.US)$ $Apple (AAPL.US)$

1

$Ascendis Pharma A/S (ASND.US)$ reporting wasn't so terrible that it deserves a15% drop. could see this rebounding above the price before the drop

1

FDA PDUFA Update…

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...

8

Nice curl! On watch for recovery. May swing.

$Ascendis Pharma A/S (ASND.US)$

1

Read more